TopiVert has delivered compelling clinical POC data for TOP1630 in the treatment of dry eye syndrome - validating its NSKI technology as topical anti-inflammatories. TOP1890 is also due to enter a Phase 1 study, with a topical oral formulation, in Q4 2018
Exciting technology platform - next generation kinase inhibitors
Our Non Systemic Kinase Inhibitors (NSKIs) are novel small molecules which specifically target a select range of kinases that mediate inflammatory disease and have topical, non-systemic availability to provide long-term safety and tolerability.
Targeting areas of high unmet need
TOP1630 is being developed for dry eye syndrome, a highly prevalent and often chronic disease which can be debilitating in severe cases. TOP1890 is being developed for ulcerative colitis, a disease in which first line therapy fails in 50% of patients, and 15% require major colon surgery.
High quality team
Our experienced management team works alongside selected experts in their field
Blue chip investors
Our investors include SV Health Investors, Touchstone Innovations, NeoMed and Johnson & Johnson Innovation – JJDC, Inc.
TopiVert is a private, clinical-stage biotechnology company developing next-generation, Non-Systemic Kinase Inhibitors (NSKIs) as novel medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye.
Our lead ophthalmology programme, TOP1630, has demonstrated proof of concept in a Phase 1/2a proof-of-concept study in the treatment of dry eye syndome in the US. TopiVert recently announced that:
“TOP1630, our lead NSKI in ophthalmology, has delivered compelling data in a Phase 1/2a proof of concept study for the treatment of dry eye syndrome. We believe that the consistency of effect demonstrated across a range of sign and symptom endpoints, from multiple assessment scales and all from pre-specified analyses, coupled with the placebo-like tolerability profile sets a new benchmark for DES treatments. This exciting programme is now ready for late stage development in an area of high unmet medical need.”
In parallel, TOP1890 for the treatment of ulcerative colitis will enter a Phase I study with an oral formulation in late 2018.
"We aim to change the lives of millions of people around the world suffering with serious diseases such as dry eye syndrome and inflammatory bowel disease - both areas with high unmet medical needs"
Hamish Cameron, Chairman of TopiVert
NSKIs are novel small molecules characterised by broad efficacy and an excellent safety profile. Each NSKI has potent activity against a select range of key kinases that play pivotal roles in multiple inflammatory pathways and has resulted in a broad synergistic effect in models of both innate and adaptive immunity. NSKIs also have non-systemic bioavailability, such that their activity is focused at the local site of disease. Together, these attributes make NSKIs ideally adapted as treatments for inflammatory diseases where long-term therapy demands a sustained effect along with high safety and tolerability. TopiVert has chosen to apply its NSKI technology to gastrointestinal and eye diseases, which are particularly amenable to topical applications and where there are major unmet needs for improved therapy.
Our high quality science and experienced management team are backed by industry leading investors. Learn more about who we are, what we are doing and what drives us forward...